KDventures portfolio company Modus Therapeutics pauses Phase 2a trial enrolment, delays expected readout

Philips-led EXIT-CVD consortium launches cardiovascular clinical studies across Europe

SciBase technology selected as primary endpoint in NIH-led skin exposure study

Continuity Biosciences awarded Gates Foundation grant to advance ultra-long-acting implant for HIV prevention

Genezen agrees manufacturing collaboration with Galibra Neuroscience

Viking Therapeutics launches Phase 3 clinical programme for oral VK2735 in obesity

Coya Therapeutics plans open-label extension of COYA 302 ALS trial

Takeda reports positive Phase 2/3 results for investigational immunodeficiency therapy

Galderma to acquire ZO Skin Health for USD1.5bn to expand skincare portfolio

Orexo reports encouraging initial bioavailability results for oral semaglutide formulation

Pharming reports positive Phase II results for leniolisib in genetic immune disorders

Telix to present 20 abstracts on cancer theranostics at EANM Congress

CelLBxHealth secures USD65,000 pharmaceutical research contract

FDA grants Breakthrough Therapy Designation to Legacy Healthcare's CINAINU (LH-8)

Racura Oncology receives approval for RC220 trial to proceed to higher dose